據(jù)8月14日的《科學》雜志報道說,，T 細胞是一種在與癌癥腫瘤的斗爭中有前途的特別的免疫細胞,；但腫瘤細胞與正常的人類細胞很好地混合在一起，因此要找到一種使得這些T 細胞能夠標靶腫瘤細胞的技術一直難以成功,。但是現(xiàn)在研究人員說,，他們已經(jīng)研發(fā)出了一種抗體蛋白,，它能夠有效地將非何杰金氏淋巴瘤病人的T 細胞與腫瘤細胞結合起來,，導致該癌癥的可測出的或是完全的消退,。
這種被稱作blinatumomab 的抗體看來對惡性腫瘤會有重大的治療潛力。Ralf Bargou 及其同僚在病人中嘗試了不同劑量的blinatumomab,，結果發(fā)現(xiàn),，在38 名病人中，在每天每平方米0.0005-0.006 毫克的劑量范圍內(nèi),，有11 名病人出現(xiàn)了明顯的治療反應和腫瘤的消退,。然而，也有相關的不良反應出現(xiàn)?，F(xiàn)在有一個正在進行的臨床II 期試驗在研究blinatumomab 在淋巴細胞性白血病患者中的活性,。（生物谷Bioon.com）
生物谷推薦原始出處：
Science 15 August 2008 321: 974-977 [DOI: 10.1126/science.1158545]
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf Bargou,1,2* Eugen Leo,3* Gerhard Zugmaier,3 Matthias Klinger,3 Mariele Goebeler,1,2 Stefan Knop,2 Richard Noppeney,4 Andreas Viardot,5 Georg Hess,6 Martin Schuler,7 Hermann Einsele,2 Christian Brandl,3 Andreas Wolf,3 Petra Kirchinger,3 Petra Klappers,3 Margit Schmidt,3 Gert Riethmüller,8 Carsten Reinhardt,3 Patrick A. Baeuerle,3 Peter Kufer3
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non–Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell–engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.
1 Interdisciplinary Phase I/II Unit of the University of Würzburg, Klinikstraße 6-8, 97070 Würzburg, Germany.
2 Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Klinikstraße 6-8, 97070 Würzburg, Germany.
3 Micromet AG, Staffelseestraße 2, 81477 Munich, Germany; and Micromet, Incorporated, 6707 Democracy Boulevard, Bethesda, MD 20817, USA.
4 Universitätsklinikum Essen, Klinik für Hämatologie, Medizinische Klinik und Poliklinik, Hufelandstraße 55, 45147 Essen, Germany.
5 Universitätsklinikum Ulm, Innere Medizin III, Robert-Koch-Straße 8, 89081 Ulm, Germany.
6 Klinikum der Johannes-Gutenberg Universität III, Medizinische Klinik und Poliklinik, Langenbeckstraße 1, 55131 Mainz, Germany.
7 Universitätsklinikum Essen, Innere Klinik (Tumorforschung), Tumorforschung, Hufelandstraße 55, 45122 Essen, Germany.
8 Institute for Immunology, Ludwig-Maximilians-Universität, Goethestraße 31, 81333 Munich, Germany.
